Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 5 publications
(6 citation statements)
references
References 8 publications
(19 reference statements)
0
6
0
Order By: Relevance
“…1 Although survival for MM has improved markedly over the last decade with the introduction of new therapeutic agents, all patients eventually relapse. 2 The global burden of MM has substantially increased in the last 30 years, but its incidence is highly variable among different countries. Although MM is more common in high sociodemographic index countries, the temporal increase in disease incidence has been higher in middle and low-middle sociodemographic index countries.…”
Section: Introductionmentioning
confidence: 99%
“…1 Although survival for MM has improved markedly over the last decade with the introduction of new therapeutic agents, all patients eventually relapse. 2 The global burden of MM has substantially increased in the last 30 years, but its incidence is highly variable among different countries. Although MM is more common in high sociodemographic index countries, the temporal increase in disease incidence has been higher in middle and low-middle sociodemographic index countries.…”
Section: Introductionmentioning
confidence: 99%
“…Elotuzumab is an immunostimulatory monoclonal antibody targeting signaling lymphocyte activation molecule F7 (SLAMF7) [157]. While no responses to elotuzumab as a single agent were obtained, the addition of elotuzumab to lenalidomide and dexamethasone in RR-MM patients resulted in overall response rate (ORR) of 79% compared to 66% ORR obtained with lenalidomide and dexamethasone alone [142,158]. Also, in a phase III randomized clinical trial in patients with R/R-MM, the combination of elotuzumab, lenalidomide and dexamethasone decreased the risks of death and disease progression by 30% [157].…”
Section: Elotuzumabmentioning
confidence: 99%
“…It is able to sensitize 24% of bortezomib-refractory MM patients. When combined with dexamethasone in R/R-MM, it resulted in superior outcome in terms of ORR and PFS compared to bortezomib and dexamethasone combination [158]. Also, it is under evaluation for patients with newly diagnosed MM [166].…”
Section: Carfilzomibmentioning
confidence: 99%
See 1 more Smart Citation
“…It can cause multiple organ dysfunctions such as renal insufficiency, anemia, frequent infection, hypercalcemia and bone destruction, which has become an increasing public health burden [2]. Although the existing therapeutic drugs against MM have shown greatly remission in the large majority of patients with newly diagnosed MM, many patients still relapse due to drug resistance [3,4]. Bortezomib, the proteasome inhibitor, is a frontline drug in the treatment of MM.…”
Section: Introductionmentioning
confidence: 99%